<?xml version="1.0" encoding="UTF-8"?>
<results title="migration">
 <result pre="Paper Metformin inhibits high glucose-induced smooth muscle cell proliferation and" exact="migration" post="ZhouDong-Ming1*RanFeng2*NiHai-Zhen34*SunLi-Li3XiaoLun2LiXiao-Qiang2LiWen-Dong2[1], [2], [3], [4], *Equal contribution Correspondence to: Xiao-Qiang"/>
 <result pre="addition, miR-142-3p mimic and siRNA were used to investigate VSMC" exact="migration" post="in the presence or absence of metformin. In the"/>
 <result pre="those effects. Metformin inhibits high glucose–induced VSMC hyperproliferation and increased" exact="migration" post="by inducing miR-142-3p-mediated inhibition of HMGB1 expression via the"/>
 <result pre="coronary atherosclerotic plaques [8] contributes to the abnormal proliferation and" exact="migration" post="of vascular smooth muscle cells (VSMCs) [9, 10]. This"/>
 <result pre="miR- 504, -200, -138 and -210, regulate the proliferation and" exact="migration" post="of VSMCs [3]. Furthermore, studies have determined that some"/>
 <result pre="atherosclerosis [17, 18] via AMPK-mediated inhibition of VSMC proliferation and" exact="migration" post="[19]. Metformin’s promotion of microRNA expression and anti-inflammatory effects"/>
 <result pre="speculated that metformin may inhibit high glucose–induced VSMC proliferation and" exact="migration" post="via microRNA–mediated inhibition of HMGB1 expression. To test that"/>
 <result pre="mM). Our findings suggest metformin inhibits glucose-induced VSMC hyperproliferation and" exact="migration" post="by inhibiting HMGB1 expression via the HMGB1-autophagy related pathway"/>
 <result pre="&amp;lt; 0.001 for between-group comparisons. Metformin inhibited high glucose-induced VSMC" exact="migration" post="via the HMGB1-autophagy related pathway To further evaluate the"/>
 <result pre="performed. The results showed significant inhibition of high glucose–induced cell" exact="migration" post="when metformin was added to the assays. Metformin also"/>
 <result pre="added to the assays. Metformin also resulted in decreased cell" exact="migration" post="under normal glucose condition (Figure 2A, 2B). In addition,"/>
 <result pre="2C). These results indicate that metformin rectifies high glucose–induced VSMC" exact="migration" post="enhancement via the HMGB1-autophagy related pathway. Figure 2 Metformin"/>
 <result pre="2 Metformin inhibited high glucose–induced vascular smooth muscle cell (VSMC)" exact="migration" post="via HMGB1-autophagy related pathway. (A) Metformin inhibited high glucose–induced"/>
 <result pre="via HMGB1-autophagy related pathway. (A) Metformin inhibited high glucose–induced VSMC" exact="migration" post="in a two dimensional scratch assay. Significant inhibition of"/>
 <result pre="in a two dimensional scratch assay. Significant inhibition of cell" exact="migration" post="was found when metformin was added in the high-glucose"/>
 <result pre="the high-glucose condition; in addition, metformin resulted in decreased cell" exact="migration" post="in the normal glucose condition. (B) Metformin inhibited high"/>
 <result pre="the normal glucose condition. (B) Metformin inhibited high glucose–induced VSMC" exact="migration" post="in a three dimensional transwell assay. Significant inhibition of"/>
 <result pre="in a three dimensional transwell assay. Significant inhibition of cell" exact="migration" post="was found when metformin was added in the high-glucose"/>
 <result pre="the high-glucose condition; in addition, metformin resulted in decreased cell" exact="migration" post="in the normal glucose condition. (C) The HMGB1-autophagy related"/>
 <result pre="result in inhibition and promotion, respectively of high glucose–induced VSMCs" exact="migration" post="via the Akt/PI3K/autophagy related pathway To further verify the"/>
 <result pre="resulted in inhibition and promotion, respectively, of high glucose–induced VSMC" exact="migration" post="via the HMGB1-autophagy related pathway. However, metformin abolished the"/>
 <result pre="LC3II levels and elevated p62 level in high glucose–induced VSMC" exact="migration" post="enhancement. However, miR-142-3p siRNA generated the reverse effects, and"/>
 <result pre="4C). These results confirm the effects of miR-142-3p on the" exact="migration" post="behavior of VSMCs in the high-glucose condition. Figure 4"/>
 <result pre="promotion, respectively, of high glucose–induced vascular smooth muscle cell (VSMC)" exact="migration" post="enhancement via the HMGB1-autophagy related pathway, whereas metformin abolished"/>
 <result pre="and LC3II and elevated p62 level in high glucose–induced VSMC" exact="migration" post="enhancement, whereas miR-142-3p siRNA caused the opposite effects and"/>
 <result pre="***p &amp;lt; 0.001 for between-group comparison. DISCUSSION Abnormal proliferation and" exact="migration" post="of VSMC, which is enhanced by inflammation in hyperglycemic"/>
 <result pre="decreased VSMC proliferation in the high-glucose condition. In addition, VSMC" exact="migration" post="was also inhibited by metformin. Finally, increased miR-142-3p expression"/>
 <result pre="increased miR-142-3p expression was shown to inhibit VSMC proliferation and" exact="migration" post="via the HMGB1-autophagy related pathway (Figure 4D). HMGB1 is"/>
 <result pre="induced autophagy by activating AMPK, resulting in decreased proliferation and" exact="migration" post="of endothelial progenitor cells [32, 33]. In the present"/>
 <result pre="study, we also found that metformin inhibits the proliferation and" exact="migration" post="of VSMC induced by elevated glucose. This might be"/>
 <result pre="upregulated by metformin [36]. It may inhibit cell proliferation and" exact="migration" post="via the WNT signaling pathway and autophagy [37–39]. In"/>
 <result pre="tumor cells [14, 40]. Consistently, we found that miR-142-3p inhibited" exact="migration" post="enhancement in high glucose–stimulated VSMC. These findings validate that"/>
 <result pre="we demonstrated that metformin inhibits high glucose–induced VSMC hyper-proliferation and" exact="migration" post="enhancement by promoting miR-142-3p–mediated inhibition of HMGB1 expression via"/>
 <result pre="and 10 mM. The concentration of metformin in the cell" exact="migration" post="assay was 5 mM. CCK-8 assay for cell growth"/>
 <result pre="were taken using microscopy at 0 and 24 h for" exact="migration" post="evaluation. Transwell assay A modified transwell assay in 24-well"/>
 <result pre="modified transwell assay in 24-well plates was used for cell" exact="migration" post="evaluation (BD Biosciences, San Jose, CA, USA). After cell"/>
 <result pre="MicroRNA-24 inhibits high glucose-induced vascular smooth muscle cell proliferation and" exact="migration" post="by targeting HMGB1.Gene. 2016; 586:268–73. 10.1016/j.gene.2016.04.02727085480 29WangY, ShanJ, YangW,"/>
 <result pre="LiNP, SongDD, RongJJ, QianAM, LiXQ. Metformin inhibits endothelial progenitor cell" exact="migration" post="by decreasing matrix metalloproteinases, MMP-2 and MMP-9, via the"/>
 <result pre="diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and" exact="migration" post="in cervical cancer cells.Eur J Pharmacol. 2018; 830:59–67. 10.1016/j.ejphar.2018.04.02729704494"/>
</results>
